c/o JLABS, 329 Oyster Point Blvd, 3rd Floor
South San Francisco
14 articles with CODA Biotherapeutics
As life sciences companies feel the burn of the current economy, one Bay Area biotech, CODA Biotherapeutics, quietly shut its doors.
CODA Biotherapeutics Announces New Preclinical Data From Epilepsy Program Showing Significant Correlation Between Gene Expression and Efficacy
Data presented at 2022 Epilepsy Foundation Pipeline Conference provide additional in vivo proof of concept for CODA's engineered receptors and activator drugs in controlling seizures.
CODA Biotherapeutics Announces Preclinical Data From Epilepsy Program to be Presented at American Society of Gene & Cell Therapy 25th Annual Meeting
CODA Biotherapeutics, Inc. today announced that preclinical data from the Company's focal epilepsy program will be featured as a poster presentation at the American Society of Gene & Cell Therapy 25th Annual Meeting being held virtually and in person, May 16-19, 2022, in Washington, D.C.
Susan Catalano, Ph.D., joined CODA Biotherapeutics as chief scientific officer after 14 years as CEO of Cognition Therapeutics, the company she founded in 2007 and took public in 2021.
CODA Biotherapeutics Names Susan Catalano, Ph.D., as Chief Scientific Officer
CODA Biotherapeutics, Inc. today announced the appointment of Susan Catalano, Ph.D., as chief scientific officer.
A member of BioSpace’s Class of 2021, CODA aims to modify neuronal cell populations using gene therapy to express a tunable ligand-gated ion channel.
CODA Biotherapeutics' Chemogenetic Gene Therapy Platform Can Control Focal Seizures in vivo
CODA Biotherapeutics, Inc. ("CODA"), today announced the presentation of preclinical data suggesting that the Company's chemogenetic gene therapy platform can control focal seizures in vivo.
CODA Biotherapeutics Closes $28 Million Financing led by Pacira BioSciences
CODA Biotherapeutics, Inc. today announced it has closed on $28 million in financing led by Pacira BioSciences, Inc.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) to Help Advance its Next-Generation Gene Therapy-Mediated Chemogenetic Platform
NINDS Small Business Innovation Research grant of $670K over two years to support CODA's neuropathic pain program Company also selected for collaboration with NIH's National Center for Advancing Translational Science
CODA Biotherapeutics Announces Research Collaboration With The Facial Pain Research Foundation
Strategic partnership supports CODA's efforts to develop gene-therapy mediated treatments and cures for trigeminal neuralgia and related neuropathic pain [20-May-2020] SOUTH SAN FRANCISCO, Calif. , May 20, 2020 /PRNewswire/ -- CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today annou
CODA Biotherapeutics Acquires Attenua and Three Clinical Stage Assets
CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today announced it has completed the acquisition of Attenua, Inc.
CODA Biotherapeutics Deepens Gene Therapy Expertise with Industry Veteran, Annahita Keravala, Ph.D., and Key Promotions
Expansion and development of leadership team drives the company's chemogenetic gene therapy platform toward the clinic in initial core therapeutic areas of chronic neuropathic pain and focal epilepsy
CODA Biotherapeutics Announces Series A Extension, Bringing Total Round to $34 Million
Proceeds will advance company's chemogenetic gene therapy platform toward the clinic with an initial focus on chronic neuropathic pain and focal epilepsy